Tocilizumab before or during CAR-T therapy
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether giving tocilizumab (a drug that calms inflammation) before CAR-T cell therapy helps prevent side effects. It compares using it ahead of time versus only when needed. You may be eligible if you are scheduled for CAR-T therapy for lymphoma, leukemia, or myeloma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled to receive CAR-T cell therapy for lymphoma, leukemia, or myeloma.
- You are at least 18 years old.
- You have not received tocilizumab in the last 3 months.
- You have not taken any other experimental drug in the last 8 weeks.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study period (unless you use highly effective birth control).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a spinal injection of three common chemotherapy drugs can reduce or prevent serious brain and nerve side effects in people receiving CAR-T cell therapy for cancer.
This trial tests whether adding low-dose total body radiation before standard CAR-T cell therapy (Kymriah) helps people with relapsed or refractory large B-cell lymphoma. It aims to improve the effectiveness of the CAR-T cells.
This trial tests itacitinib given before CAR T cell therapy to see if it can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL). It may help by calming certain immune signals before CAR T is started.
This trial tests giving the drug iberdomide before collecting your T cells for CAR-T therapy. The goal is to make the T cells stronger so the CAR-T treatment may work better against your multiple myeloma.
This Phase 1 study tests a CAR-T cell treatment made to target CD19 in children and young adults whose leukemia or lymphoma has come back or did not respond to prior treatment. It aims to see how the treatment works and how safe it is in this age group.
This study looks at how the type of chemotherapy given before CAR T-cell treatment affects how well the CAR T-cells work in people with aggressive large B-cell lymphoma that has come back or not responded to treatment. It aims to find out which pre-treatment approach leads to better outcomes.
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.